Circulating Tumor Cells Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Japan, China, India, Brazil, Mexico, Saudi Arabia, South Africa), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025
Report ID: GMI4109
Circulating Tumor Cells Market size is projected to experience significant growth from 2019 to 2025.
The circulating tumor cells (CTC) market is estimated to witness considerable growth over the forth coming years. High growth is attributed to increasing prevalence of cancer worldwide. As per the National Cancer Institute, cancer causes major healthcare issues for the population of U.S. and across the globe. It is estimated that in 2018, 1,735,350 cases of cancer have been registered and the prevalence rate is expected to grow in the future thus, augmenting circulating tumor cells market growth.
Increasing technological advancements in the biomedical imaging and bioengineering processes will further propel market growth. Several CTC technologies have been proposed in the recent years by various companies and research groups, that will lead to early cancer prognosis thus, providing ample time to cure the disease.
On the contrary, dearth of awareness among the population regarding various CTC technologies along with reluctance for the adoption of novel CTC technologies will restrain the market growth. Furthermore, stringent government regulations regarding approval of CTC technologies is another major growth hindering factor.
The negative enrichment method segment is expected to witness significant growth across the forecast timeframe. Negative enrichment method, an epithelial marker can isolate intact and heterogenous CTC’s by explicitly removing blood cells. It displays a better efficiency in detecting the CTCs compared to positive enrichment method. Moreover, diagnostic centers and other medical facilities prefer negative enrichment method over others due to its efficiency in detecting CTC’s. Hence, the above-mentioned reasons will augment segmental growth.
Multiple chromosome abnormalities segment is expected to hold major chunks of revenue over the forecast years. The most common type of chromosomal abnormality is aneuploidy, where due to a missing or extra chromosome an abnormal chromosome number is formed. Hence, rising prevalence of multiple chromosome abnormality syndromes will augment segmental growth across the forecast period.
By end use, the market comprises hospitals, research and academic institutes and clinics, and diagnostic centers. The hospital segment is expected to witness maximum growth over the forecast period. Hospitals offer state-of-the-art facilities for appropriate CTC tests at an affordable rate. CTC tests such as positive enrichment and negative enrichment test are mostly performed in hospitals owing to availability of desired healthcare settings. Additionally, increasing preference of people in the developing economies for hospitals over other medical facilities due to affordability will further augment market growth.
The U.S. is expected to witness substantial growth over the forecast period owing to the presence of sophisticated healthcare infrastructure, technological advancements and skilled professionals. Furthermore, increasing prevalence of cancer in the U.S. will further propel market growth. Additionally, rising initiatives by various companies and research firms to manufacture advance technologies with the aim to deliver efficient results for circulating tumor cells test is another major reason to escalate market growth.
China is expected to witness significant growth in the circulating tumor cells market during the analysis period. High growth is attributed to increasing prevalence of cancer in various parts of China. As per National Institute of Health, with increasing mortality, cancer is the foremost cause of death in China and is a major public health problem thus, propelling market growth.
Some of the key industry players include Aviva Biosciences, Advanced Cell Diagnostics Inc., Biocept Inc., LungLife AI Inc., Creatv Micro Tech, Inc., Miltenyi Biotec, Menarini Silicon Biosystems, Precision for Medicine and Qiagen NV. Key strategies adopted by industry players include strategic collaborations, partnerships, mergers, and innovative product launch to expand their business product portfolio.
Circulating Tumor Cells Market by Technology, 2014-2025 (USD Million)
- CTC enrichment methods
- Positive enrichment
- Negative enrichment
- CTC detection methods
- Immunocytochemical technology
- Molecular (RNA)-based technology
Circulating Tumor Cells Market by Application, 2014-2025 (USD Million)
- Multiple chromosome abnormalities
- RNA profiling
- Protein expression
- Cellular communication
Circulating Tumor Cells Market by End-use, 2014-2025 (USD Million)
- Research & academic institutes
- Hospital & clinics
- Diagnostic centers
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- Advanced Cell Diagnostics Inc.
- Aviva Biosciences
- Biocept Inc.
- Creatv Micro Tech, Inc.
- LungLife AI Inc.
- Menarini Silicon Biosystems
- Miltenyi Biotec
- Precision for Medicine
- Qiagen NV
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Why Global Market Insights, Inc.?
- GMI is unparalleled when to comes to the quality of research and information provided to clients. Our unique methodology is designed to ensure a minimum of 90% accuracy to give our clients excellent value on their investment.
Over 200 experts are available across various time-zones, ready to serve clients for their research needs. Our industry experts help clients to design reports customized to their needs.